• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.
【24h】

Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.

机译：Atacicept，一种靶向B细胞的新型生物疗法，用于治疗类风湿关节炎。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Recent data suggest a key role for B cells in the pathogenesis of many autoimmune diseases including rheumatoid arthritis (RA), and biological therapies targeting B cells are promising treatments for patients with RA. Atacicept inhibits B cell maturation, differentiation and survival, and immunoglobulin production by depriving B cells of growth and development signals. Therefore, atacicept may represent an effective strategy in RA treatment. OBJECTIVE: To evaluate the potential value of atacicept in RA treatment based on preclinical and clinical studies. METHODS: Preclinical and clinical data on atacicept were identified using PubMed and systematically reviewed. RESULTS/CONCLUSION: Preclinical and clinical studies show that atacicept is well tolerated, with no increased incidence of infections. Atacicept displays non-linear pharmacokinetics, with a more than dose-proportional increase in free drug and less than dose-proportional, saturated increase in atacicept-ligand complex. Overall, the pharmacokinetic profiles of atacicept were consistent, dose-related and predictable. Dose-dependent reductions in immunoglobulins and other biomarkers, including rheumatoid factor, occurred rapidly but returned to baseline after discontinuation. There was a biphasic response in B cell number, but no effect on other leucocytes. Atacicept improved the signs and symptoms of RA, although larger studies are needed to confirm its efficacy and its optimal use.
机译：背景：最近的数据表明，B细胞在包括风湿性关节炎（RA）在内的许多自身免疫性疾病的发病机理中起着关键作用，针对B细胞的生物疗法是治疗RA患者的有前途的疗法。 Atacicept通过剥夺B细胞的生长和发育信号来抑制B细胞的成熟，分化和存活以及免疫球蛋白的产生。因此，atacicept可能代表RA治疗的有效策略。目的：根据临床前和临床研究评估阿他西普在RA治疗中的潜在价值。方法：使用PubMed鉴定了有关atacicept的临床前和临床数据，并对其进行了系统地审查。结果/结论：临床前和临床研究表明，atacicept具有良好的耐受性，感染率没有增加。 Atacicept显示出非线性的药代动力学，游离药物的剂量比例增加幅度大于剂量比例，而atacicept-配体复合物的饱和剂量幅度小于剂量比例的饱和浓度。总体而言，atacicept的药代动力学特征是一致的，剂量相关的和可预测的。免疫球蛋白和其他生物标记物（包括类风湿因子）的剂量依赖性减少迅速发生，但停药后又恢复到基线。 B细胞数量呈双相反应，但对其他白细胞无影响。尽管需要更大的研究来证实它的疗效和最佳使用，但Atacicept改善了RA的体征和症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号